Recent studies on gene therapy vectors for hemophilia have highlighted the varying effectiveness and risks associated with different AAV isotypes and gene constructs. Dosages ranging from 2 × 10^11 vector genome [vg]/kg to 6 × 10^13 vg/kg have been tested, showing significant reduction in bleeds for both hemophilia A and hemophilia B patients. Phase-1 trials […]